These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 16139891)

  • 1. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
    Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new models for the analysis of Fc-FcRn interactions.
    Gurbaxani BM; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1379-89. PubMed ID: 16183124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative methods for developing Fc mutants with extended half-lives.
    Kamei DT; Lao BJ; Ricci MS; Deshpande R; Xu H; Tidor B; Lauffenburger DA
    Biotechnol Bioeng; 2005 Dec; 92(6):748-60. PubMed ID: 16136591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FcRn mediates elongated serum half-life of human IgG in cattle.
    Kacskovics I; Kis Z; Mayer B; West AP; Tiangco NE; Tilahun M; Cervenak L; Bjorkman PJ; Goldsby RA; Szenci O; Hammarström L
    Int Immunol; 2006 Apr; 18(4):525-36. PubMed ID: 16481343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
    J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin binding to FcRn: distinct from the FcRn-IgG interaction.
    Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL
    Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FcRn binding properties of an abnormal truncated analbuminemic albumin variant.
    Andersen JT; Daba MB; Sandlie I
    Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.
    Magistrelli G; Malinge P; Anceriz N; Desmurs M; Venet S; Calloud S; Daubeuf B; Kosco-Vilbois M; Fischer N
    J Immunol Methods; 2012 Jan; 375(1-2):20-9. PubMed ID: 21939661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the serum persistence of an IgG fragment by random mutagenesis.
    Ghetie V; Popov S; Borvak J; Radu C; Matesoi D; Medesan C; Ober RJ; Ward ES
    Nat Biotechnol; 1997 Jul; 15(7):637-40. PubMed ID: 9219265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
    Zuckier LS; Chang CJ; Scharff MD; Morrison SL
    Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta 2-microglobulin deficient mice catabolize IgG more rapidly than FcRn- alpha-chain deficient mice.
    Kim J; Bronson CL; Wani MA; Oberyszyn TM; Mohanty S; Chaudhury C; Hayton WL; Robinson JM; Anderson CL
    Exp Biol Med (Maywood); 2008 May; 233(5):603-9. PubMed ID: 18375831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues.
    Andersen JT; Justesen S; Fleckenstein B; Michaelsen TE; Berntzen G; Kenanova VE; Daba MB; Lauvrak V; Buus S; Sandlie I
    FEBS J; 2008 Aug; 275(16):4097-110. PubMed ID: 18637944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.